INSUBCONTINENT EXCLUSIVE:
funding.The round is led by Lux Capital and Obvious Ventures, with participation from Felicis Ventures, Inovia Capital, Air Street Capital
full-stack protein engineering company: we combine artificial intelligence (AI), robotic automation and synthetic biology to evolve
an age in which humans will no longer be the sole agents of innovation
Instead, new knowledge, technologies and sophisticated real-world products will be invented by smart robotic platforms called empirical
The rapid pace of technological development across the fields of synthetic biology, robotic automation and ML has given us access to all the
antibody fragments capable of treating conditions that cannot be addressed using conventional antibody formats.
